A recent early-phase trial combining revumenib, a menin inhibitor, with established AML treatments showed promising remission rates in genetically defined acute myeloid leukemia patients, leading to planned Phase 3 studies. Additionally, CD97-targeting CAR-T cells demonstrated enhanced persistence and antitumor activity in AML xenograft models, offering a potential advancement in therapy for aggressive blood cancers. Research continues to target resistance mechanisms and improve efficacy in immunotherapies and targeted agents.